- June 28, 2022
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to
Telegraph Hill Partners, founded in 2001, is a venture capital firm dedicated to helping life science, medical device and healthcare companies achieve their growth objectives. When you work with us, you get an experienced team that knows how to efficiently drive growth and profitability while maintaining the vision and integrity of the organization.
We partner with private life science and healthcare companies that have novel technologies, a solid customer base, and innovative management teams. We make investments into high-quality companies looking for capital to help build and grow their organizations. We encourage you to contact us to learn more about Telegraph Hill Partners.
360 Post Street
Suite 601
San Francisco, CA 94108